Synlogic (NASDAQ:SYBX) is set to release its earnings data after the market closes on Tuesday, November 13th. Analysts expect Synlogic to post earnings of ($0.64) per share for the quarter.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.06). The company had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.22 million. Synlogic had a negative return on equity of 43.51% and a negative net margin of 5,949.04%. On average, analysts expect Synlogic to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of SYBX stock opened at $7.99 on Friday. The firm has a market capitalization of $204.85 million, a price-to-earnings ratio of -1.36 and a beta of 2.62. Synlogic has a 52 week low of $7.27 and a 52 week high of $15.00.

Several analysts have recently issued reports on SYBX shares. Citigroup upgraded shares of Synlogic from a “neutral” rating to a “buy” rating in a research report on Friday, August 24th. Zacks Investment Research cut shares of Synlogic from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. HC Wainwright set a $20.00 target price on shares of Synlogic and gave the company a “buy” rating in a research report on Tuesday, October 9th. Finally, Wedbush restated an “outperform” rating on shares of Synlogic in a research report on Friday, September 7th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $17.93.

In other news, insider Paul Francis Miller sold 3,000 shares of the company’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $9.76, for a total transaction of $29,280.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 12,000 shares of company stock worth $135,390 over the last 90 days. Corporate insiders own 23.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Synlogic (SYBX) Set to Announce Earnings on Tuesday” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at

About Synlogic

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Further Reading: What is an Initial Public Offering (IPO)?

Earnings History for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with's FREE daily email newsletter.